News – EN – Ipsen: new data on Somatuline Autogel

For security reasons and to continue to access your member area, we thank you for validating your member account by clicking on the following link:
I validate my member account
You will receive an email at the address indicated when you created your account

Then click on the link in the email You can then access your member account again

If you have not received this email,
contact us

8 characters minimum

1 uppercase

1 lowercase

1 digit

1 special character

Different from your nickname

Both passwords are the same

Benefit from additional features and services free of charge
Become a member

New to Boursorama?
Become a member

(CercleFinancecom) – Ipsen unveiled on Monday the results of a phase II study showing that the increase in the frequency of administration of Somatuline Autogel, its treatment against neuroendocrine tumors, did not affect the quality of life of patients

According to the company, these new results reveal that the quality of life remained stable throughout the study in patients with tumors of the pancreas and digestive tract, despite injections twice as frequent compared to their initial dosing schedule

These abstracts were published on the occasion of the ENETS (European Neuroendocrine Tumor Society) congress, specifies Ipsen in a press release.

In the United Kingdom, where the autonomous injection of the gel at home by the patient or a partner has been approved, a substantial impact in terms of cost reduction and hospital consultations has also been observed, notes the pharmaceutical group on Monday

Ipsen share is currently up 0.6% in a Paris market down 0.6%

You must be a member to add a comment

Already a member ?
Log in

Not a member yet ?
Join for free

Ipsen, Lanreotide, Neuroendocrine tumor, Quality of life, Octreotide, Health Care, Medicine